The Acute Intermittent Porphyria Market Highlights:
Porphyria is a disorder that occurs when there is a build-up of the chemicals in the body that produce a substance called porphyrin. Acute intermittent porphyria (AIP) is a genetic metabolic disorder is one of the 8 types of porphyria. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Children have a 50% chance of inheriting any of the 8 different types of porphyria if their parents have the disorder.
Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.
The global acute intermittent porphyria market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/4713 .
Acute Intermittent Porphyria Market Regional Analysis:
The Americas dominate the global acute intermittent porphyria market owing to the presence of huge patient population with gastrointestinal problems, neurological issues, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global acute intermittent porphyria market as result of increasing focus of various government agencies on the treatment of rare diseases such as acquired aplastic anemia. Moreover, the growing public awareness about acquired aplastic anemia likely to boost the Europe market.
Asia Pacific is the fastest growing acute intermittent porphyria market across the globe. Japan holds the major share of the regional market due to availability of advanced technology and huge healthcare spending. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in China and India over the forecasted period.
The Middle East and Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market.
The Acute Intermittent Porphyria Market Segmentation:
The global acute intermittent porphyria market is segmented on the basis by diagnosis, by treatment, and by end user. On the basis of diagnosis, it is segmented into blood test, urine test, serum test, DNA test, and others. On the basis of treatment, it is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others. On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.
Acute Intermittent Porphyria Market Key Players:
Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), and ACON Laboratories, Inc. (U.S.)
Top 5 Reasons to Get this Report:
Company profiling with detailed strategies, financials, and recent development activities
Market Strategic Business Influence Data
Market Research Future recommendations in key business segments based on the market estimations
Market share analysis of the top industry players
Market forecasts for a minimum of 5 years of all the mentioned segments, Trends and the regional markets With SWOT Analysis
Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/4713 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312